Navigation Links
Inovio Pharmaceuticals to Present at Scientific Conferences
Date:3/29/2011

BLUE BELL, Pa., March 29, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company will make presentations at two scientific conferences:Immunopotentiators in Modern VaccinesPorto, Portugal, April 6-8, 2011Tiara Park Atlantico HotelInovio PresentationAmir Khan, Ph.D., Director of Product DevelopmentApril 7, 2011Session 8"Development of molecular adjuvants for DNA vaccines"http://www.meetingsmanagement.com/imv_2011/index.htmWorld Vaccine CongressWashington, D.C., April 11-14, 2011Gaylord National Hotel and Convention CenterInovio PresentationsNiranjan Sardesai, Ph.D., Sr. VP, Research and Development April 12, 20112:10pm Stream BDesigning DNA-based vaccines with the capability to provide universal protection against unmatched influenza virus strainsApril 12, 20115:50pm Stream BPanel session: Universal influenza vaccine: what challenges must be overcome to ensure feasibility?April 13, 20113:25pm Stream APanel session: Funding and reimbursement: a new dealmaking hurdle?http://www.terrapinn.com/conference/world-vaccine-congress-washington/About Inovio Pharmaceuticals, Inc.Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio's clinical programs include three separate programs in Phase II clinical studies, including VGX-3100 for treating cervical dysplasia and cancer. Other Inovio clinical programs include those for avian flu (preventive) and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010 and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.com

Media: Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com

(Logo: http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)


'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Receives U.S. DOD Small Business Innovation Research Grant for Multi-Vaccine DNA Delivery Device Development
2. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
3. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
4. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
5. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
6. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
7. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
8. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
9. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
10. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
11. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
(Date:4/18/2017)... April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and providing ... is in conjunction with this morning,s announcement of the ... and Nutritional Insufficiency businesses. Cardinal Health now ... will be at the bottom of its previous guidance ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... The National ... upon National Registry of Emergency Medical Technicians and welcomes this organization ... Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers more effectively ... dairy proteins, providing direct cost savings as well as more stable pricing over ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... signed an agreement to be the preferred physical therapy provider for Derby City ... them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s sports ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by ... to receive dental care. The doctors offer three treatment options to put victims of ... surgery, at their dental office in Vancouver. Wall Centre Dental is currently welcoming even ...
(Date:4/25/2017)... ... 25, 2017 , ... Back Pain Centers of America (BPC), which ... physician in their area, announces the launch of a new and proprietary customer relationship ... looking for reputable physicians to help them with back or neck pain and helps ...
Breaking Medicine News(10 mins):